Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forget DTC; Get Ready for DFC: Using Social Media to Detect Safety Signals Direct From Consumers

This article was originally published in RPM Report

Executive Summary

The past decade has witnessed the importance of DTC pharma messages. With social media tracking and internet search signal detection, is the US at the edge of a DFC era? Will safety signals scraped from internet inquiries and social media conversations be the next wave source of drug safety concerns? A special subcommittee of FDA’s Science Board released a report at the beginning of May that advises FDA to pay attention to the opportunities from new media for picking up drug safety signals.

You may also be interested in...



Surveying the Landscape for Active Surveillance

The transition away from spontaneous adverse event reporting systems to real-time active surveillance is under way, but far from complete. Alan Goldhammer, the former head of regulatory affairs at the Pharmaceutical Research & Manufacturers of America trade association, surveys the landscape of active surveillance activities.

The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA

Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.

AAV Vector Consortia Address Quality Assays, Endpoints

Two outside groups aim to help CBER on gene therapy questions from ‘N of one’ to markers for hemophilia.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel